TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET

GlobeNewsWire • Feb 23, 2026

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 23, 2026

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS

GlobeNewsWire • Feb 8, 2026

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below.

GlobeNewsWire • Feb 6, 2026

Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares

Hussman Stratgic Advisors sold 126,000 shares of TG Therapeutics. The fund no longer holds any shares.

The Motley Fool • Feb 2, 2026

TG Therapeutics: The "Exit Velocity" You Can't Ignore (Rating Upgrade)

TG Therapeutics (TGTX) is upgraded from Hold to Strong Buy as BRIUMVI demonstrates accelerating revenue growth and market share gains in the MS market. TGTX guides for 2026 BRIUMVI U.S. net revenue of $825–$850 million, implying ~40% YoY growth and continued base expansion beyond Q4 2025 run rate. Strategic low pricing, administrative simplification, and subcutaneous formulation development underpin TGTX's competitive positioning and future margin expansion.

Seeking Alpha • Jan 15, 2026

These under-the-radar stocks combine fast growth with big upside potential

The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.

Market Watch • Jan 15, 2026

TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results

TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.

Zacks Investment Research • Jan 14, 2026

TG Therapeutics Stock Climbs After The Bell: Here's Why

TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here's a look at the details.

Benzinga • Jan 13, 2026

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026